Bundibugyo Virus Outbreak Response Vaccines (BundiVx) - RRPV Consortium
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Contract Value
Not provided
Codes & Classification
Solicitation Number
RRPV-26-13-BundiVx
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AN23
Additional Details
Documents4
The Office of Biomedical Advanced Research and Development Authority (BARDA), operating within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), has issued a solicitation under the Rapid Response Partnership Vehicle (RRPV) Consortium. This initiative, titled "Bundibugyo Virus Outbreak Response Vaccines (BundiVx)," seeks to leverage collaborative efforts between industry and academia to advance research and development activities targeting the Bundibugyo virus (BDBV).
The primary objective of this procurement is to accelerate the development of investigational BDBV vaccine candidates utilizing the Vesicular Stomatitis Virus (VSV) vaccine platform, which has previously demonstrated efficacy in single-dose protection during Ebola virus (EBOV) outbreaks. The scope of work encompasses several critical phases, beginning with manufacturing process development and culminating in the production of initial current Good Manufacturing Practice (cGMP) Phase 1 clinical trial material (CTM), with a target of up to 10,000 doses. Early regulatory engagement is emphasized to inform the IND-enabling nonclinical pathway, ensuring alignment with U.S. Food and Drug Administration (FDA) requirements.
Offerors are expected to detail how efficiencies from prior or ongoing platform development and manufacturing can be harnessed to expedite cGMP CTM production and IND submission. The solicitation also includes provisions for conducting a Phase 1 safety and immunogenicity trial, with options to scale production up to 100,000 doses of cGMP CTM as needed. The overarching goal is twofold: to produce cGMP CTM and meet regulatory requirements for clinical trial use during the ongoing 2026 BDBV outbreak, and to identify promising BDBV vaccine candidates for potential further development.
This opportunity is classified under NAICS Code 541714, "Research and Development in Biotechnology (except Nanobiotechnology)," and Product Service Code AN23. There are no set-aside requirements, making it open to all qualified entities. The place of performance is Washington, District of Columbia, United States.
The contracting entity is BARDA - ASPR / DAAPPO / BARDA DCMA, a federal office within HHS. The primary point of contact for this solicitation is Veronica Stroud ([email protected], 202-731-3103), with Jonathan Gonzalez serving as the Contracting Officer ([email protected]).
Interested parties should note the revised submission deadline of July 2, 2026. Questions regarding the solicitation are due by June 16, 2026, at 12 p.m. Eastern, and proposals must be submitted by June 26, 2026, at 3 p.m. Eastern. Additional information, including question and answer documents and other attachments, is available via the solicitation link: https://www.rrpv.org/solicitation/bundibugyo-virus-outbreak-response-vaccines-bundivx/. The official notice can also be accessed on SAM.gov under Opportunity ID 39416da2c4234eb6be171677294465c5.
Contractors with expertise in biotechnology research and development, particularly those experienced in vaccine platform technologies and cGMP manufacturing, are encouraged to review the solicitation and associated documents to assess alignment with their capabilities. The requirements and objectives outlined in this notice are expected to remain consistent throughout the contract lifecycle, focusing on rapid response vaccine development and regulatory readiness for outbreak response.